|  |  |
| --- | --- |
|  | [INSTITUTION ADDRESS] |

[DATE]

[REFERRAL PHYSICIAN’S NAME]

[ADDRESS]

[**Dear Doctor [NAME]**

[ADDRESS]

Example: [STUDY NAME] is a multi-centre, phase II study of doublet immunotherapy (durvalumab + tremelimumab) in combination with standard chemotherapy regimens (gemcitabine and nab-paclitaxel) versus standard chemotherapy in patients with newly diagnosed, untreated, metastatic pancreatic adenocarcinoma.

Patients will be randomized in a 2:1 ratio (doublet immunotherapy:standard chemotherapy). Efficacy for all patients will be assessed by objective tumour assessments every 8 weeks until treatment discontinuation due to progression or toxicity. All patients will be followed every 3 months for survival after progression is confirmed.

The primary end point is Progression Free Survival (PFS). The main secondary end points are Overall Response Rate (ORR), Duration of Response (DoR), overall survival (OS), safety and tolerability

[STUDY NAME] is currently recruiting patients and more information about the study main criteria can be found in the following pages.

Please feel free to refer your patients or contact me for more information about this trial.

Sincerely,

[REFERRAL PHYSICIAN’S NAME]

[ADDRESS]

|  |  |
| --- | --- |
| [PHYSICIAN’S EMAIL] |  |

|  |  |  |
| --- | --- | --- |
|  | |  |
| **Your patients may be eligible for the** [STUDY NAME] **if they have:** |  |
|  |  |

**Noteworthy Inclusion Criteria:**

* Age ≥18 years at the time of screening
* Patients must have histologically or cytologically confirmed pancreatic ductal adenocarcinoma which is metastatic.
* Tumor tissue either archival or lesion suitable for fresh tumor biopsy
* No prior systemic chemotherapy for recurrent or metastatic disease
* WHO/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

**Noteworthy Exclusions include:**

* Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumours curatively treated with no evidence of disease for > 5 years.
* Any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab.
* History of primary immunodeficiency

Please contact our study coordinator, [COORDINATOR’S NAME], at [COORDINATOR’S PHONE NUMBER] to refer patients you believe are eligible to be included to the [STUDY NAME]. We will be happy to provide additional information about the study.

More information can be found at <http://clinicaltrials.gov> identifier [NCT NUMBER]

Please do not hesitate to contact us if you need any further information.

Sincerely yours,

[COORDINATOR NAME]

[COODINATOR ADDRESS]